NO986034L - Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV - Google Patents

Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV

Info

Publication number
NO986034L
NO986034L NO986034A NO986034A NO986034L NO 986034 L NO986034 L NO 986034L NO 986034 A NO986034 A NO 986034A NO 986034 A NO986034 A NO 986034A NO 986034 L NO986034 L NO 986034L
Authority
NO
Norway
Prior art keywords
hiv
combinations
amino
ftc
zidovudþn
Prior art date
Application number
NO986034A
Other languages
English (en)
Norwegian (no)
Other versions
NO986034D0 (no
Inventor
Martha Heiden St Clair
David Walter Barry
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614022.3A external-priority patent/GB9614022D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO986034D0 publication Critical patent/NO986034D0/no
Publication of NO986034L publication Critical patent/NO986034L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO986034A 1996-06-25 1998-12-22 Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV NO986034L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2054396P 1996-06-25 1996-06-25
US2102796P 1996-07-02 1996-07-02
GBGB9614022.3A GB9614022D0 (en) 1996-07-04 1996-07-04 Antiviral therapeutic combinations
PCT/EP1997/003247 WO1997049411A1 (en) 1996-06-25 1997-06-23 Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv

Publications (2)

Publication Number Publication Date
NO986034D0 NO986034D0 (no) 1998-12-22
NO986034L true NO986034L (no) 1999-02-23

Family

ID=27268358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO986034A NO986034L (no) 1996-06-25 1998-12-22 Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV

Country Status (26)

Country Link
US (1) US6544961B1 (is)
EP (1) EP0938321B1 (is)
JP (1) JP2000515852A (is)
KR (1) KR20000022226A (is)
CN (1) CN1228026A (is)
AP (1) AP9801419A0 (is)
AT (1) ATE257708T1 (is)
AU (1) AU727983B2 (is)
BR (1) BR9709939A (is)
CA (1) CA2258956A1 (is)
CO (1) CO4900074A1 (is)
CZ (1) CZ429498A3 (is)
DE (1) DE69727240T2 (is)
EA (1) EA001517B1 (is)
ES (1) ES2213217T3 (is)
HU (1) HUP9903249A3 (is)
ID (1) ID19490A (is)
IL (1) IL127351A0 (is)
IS (1) IS4915A (is)
NO (1) NO986034L (is)
NZ (1) NZ333099A (is)
PL (1) PL330747A1 (is)
TR (1) TR199802704T2 (is)
TW (1) TW469132B (is)
WO (1) WO1997049411A1 (is)
YU (1) YU58398A (is)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
WO1999060988A2 (en) * 1998-05-29 1999-12-02 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
NZ554779A (en) * 2005-02-01 2011-02-25 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts
ES2279707B1 (es) * 2005-11-10 2008-06-01 Combino Pharm, S.L. Formulaciones orales que comprenden 3'-azidonucleosidos.
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
CN101809024A (zh) * 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
US20110053879A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
AU2011209788C1 (en) 2010-01-27 2014-08-28 Viiv Healthcare Company Antiviral therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992020344A1 (en) 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
KR100336699B1 (ko) 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
GB9503850D0 (en) 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
TW536403B (en) 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy

Also Published As

Publication number Publication date
KR20000022226A (ko) 2000-04-25
WO1997049411A1 (en) 1997-12-31
PL330747A1 (en) 1999-05-24
CZ429498A3 (cs) 1999-06-16
AU3262797A (en) 1998-01-14
NO986034D0 (no) 1998-12-22
NZ333099A (en) 2000-06-23
ATE257708T1 (de) 2004-01-15
EP0938321B1 (en) 2004-01-14
EA199801045A1 (ru) 1999-08-26
HUP9903249A3 (en) 2001-04-28
CN1228026A (zh) 1999-09-08
CO4900074A1 (es) 2000-03-27
BR9709939A (pt) 1999-08-10
EP0938321A1 (en) 1999-09-01
DE69727240D1 (de) 2004-02-19
CA2258956A1 (en) 1997-12-31
TW469132B (en) 2001-12-21
YU58398A (en) 1999-11-22
IL127351A0 (en) 1999-10-28
AU727983B2 (en) 2001-01-04
HUP9903249A2 (hu) 2000-10-28
ES2213217T3 (es) 2004-08-16
US6544961B1 (en) 2003-04-08
DE69727240T2 (de) 2004-11-25
ID19490A (id) 1998-07-16
EA001517B1 (ru) 2001-04-23
TR199802704T2 (xx) 1999-03-22
JP2000515852A (ja) 2000-11-28
IS4915A (is) 1998-11-30
AP9801419A0 (en) 1998-12-31

Similar Documents

Publication Publication Date Title
CA2216634A1 (en) Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc
NO986034L (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV
NO20053817L (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
BR0008447A (pt) Métodos de tratamento de distúrbios mitocondriais
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
BR9911612A (pt) Composições de pirrolo[2,3d]pirimidina e seus usos
EP1062950A3 (en) 1,3 Oxathiolane nucleoside analogues
WO2007044357A3 (en) Formulations of aica riboside
BR0311154A (pt) Composição para melhorar o melasma e composição para reduzir a opacidade da pele
NO20005332L (no) 1,6-GPS-(6-O-α-D-glukopyranosyl-D-sorbit) og 1,1-GPM-(1-O-α-D-glukopyranosyl-D-mannit)-holdig sukkeralkoholblanding for bruk som terapeutisk aktivt stoff samt legemiddel inneholdende nevnte blanding
EA199900757A1 (ru) Фармацевтические композиции
AR023661A1 (es) Combinaciones antivirales
NO986035L (no) Kombinasjoner omfattende VX478, zidovudin og/eller 1592U89 for anvendelse i behandling av HIV
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
WO2001030329A3 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
NO995620L (no) Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89
AR007616A1 (es) Combinaciones antivirales
AR043332A1 (es) Composiciones y metodos para terapia antiviral
AR007615A1 (es) Combinaciones antivirales, formulaciones conteniendo las mismas, uso de los mismos en la manufactura de medicamentos y un articulo que los contiene.
ES2173027A2 (es) Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral
TH34798A (th) การรวมสารต้านไวรัส
Van Bavel Back Matter (" Index")

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application